Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative diseases, characterized by the accumulation of extracellular amyloid plaques and intraneuronal neurofibrillary tangles. These tangles mainly consist of hyperphosphorylated tau protein. As it induces tau hyperphosphorylation in vitro and in vivo, hypothermia is a useful tool for screening potential neuroprotective compounds that ameliorate tau pathology. In this study, we examined the effect of prolactin-releasing peptide (PrRP), its lipidized analog palm11-PrRP31 and glucagon-like-peptide-1 agonist liraglutide, substances with anorexigenic and antidiabetic properties, on tau phosphorylation and on the main kinases and phosphatases involved in AD development. Our study was conducted in a neuroblastoma cell line SH-SY5Y and rat primary neuronal cultures under normothermic and hypothermic conditions. Hypothermia induced a significant increase in tau phosphorylation at the pThr212 and pSer396/pSer404 epitopes. The palmitoylated analogs liraglutide and palm11-PrRP31 attenuated tau hyperphosphorylation, suggesting their potential use in the treatment of neurodegenerative diseases.
MayeuxR, SternY (2012) Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med2, a006239.
2.
GlennerGG, WongCW (1984) Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun120, 885–890.
3.
BueeL, BussiereT, Buee-ScherrerV, DelacourteA, HofPR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev33, 95–130.
4.
TournissacM, VandalM, FrancoisA, PlanelE, CalonF (2017) Old age potentiates cold-induced tau phosphorylation: Linking thermoregulatory deficit with Alzheimer’s disease. Neurobiol Aging50, 25–29.
BlennowK, de LeonMJ, ZetterbergH (2006) Alzheimer’s disease. Lancet368, 387–403.
7.
LiuY, LiuF, Grundke-IqbalI, IqbalK, GongCX (2009) Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease. J Neurochem111, 242–249.
8.
GudalaK, BansalD, SchifanoF, BhansaliA (2013) Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig4, 640–650.
9.
El KhouryNB, GratuzeM, PetryF, PaponMA, JulienC, MarcouillerF, MorinF, NichollsSB, CalonF, HebertSS, MaretteA, PlanelE (2016) Hypothermia mediates age-dependent increase of tau phosphorylation in db/db mice. Neurobiol Dis88, 55–65.
10.
GratuzeM, El KhouryNB, TurgeonA, JulienC, MarcouillerF, MorinF, WhittingtonRA, MaretteA, CalonF, PlanelE (2017) Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: Importance of thermoregulation in linking diabetes and Alzheimer’s disease. Neurobiol Dis98, 1–8.
11.
WangB, ChandrasekeraPC, PippinJJ (2014) Leptin- and leptin receptor-deficient rodent models: Relevance for human type 2 diabetes. Curr Diabetes Rev10, 131–145.
12.
HummelKP, DickieMM, ColemanDL (1966) Diabetes, a new mutation in the mouse. Science153, 1127–1128.
13.
BrettevilleA, MarcouillerF, JulienC, El KhouryNB, PetryFR, PoitrasI, MouginotD, LevesqueG, HebertSS, PlanelE (2012) Hypothermia-induced hyperphosphorylation: A new model to study tau kinase inhibitors. Sci Rep2, 480.
14.
PlanelE, MiyasakaT, LauneyT, ChuiDH, TanemuraK, SatoS, MurayamaO, IshiguroK, TatebayashiY, TakashimaA (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: Implications for Alzheimer’s disease. J Neurosci24, 2401–2411.
15.
WhittingtonRA, BrettevilleA, DicklerMF, PlanelE (2013) Anesthesia and tau pathology. Prog Neuropsychopharmacol Biol Psychiatry47, 147–155.
16.
VandalM, WhitePJ, TournissacM, TremblayC, St-AmourI, Drouin-OuelletJ, BousquetM, TraversyMT, PlanelE, MaretteA, CalonF (2016) Impaired thermoregulation and beneficial effects of thermoneutrality in the 3xTg-AD model of Alzheimer’s disease. Neurobiol Aging43, 47–57.
17.
PlanelE, RichterKE, NolanCE, FinleyJE, LiuL, WenY, KrishnamurthyP, HermanM, WangL, SchachterJB, NelsonRB, LauLF, DuffKE (2007) Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci27, 3090–3097.
18.
HooperC, KillickR, LovestoneS (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem104, 1433–1439.
19.
ShahK, LahiriDK (2014) Cdk5 activity in the brain - multiple paths of regulation. J Cell Sci127, 2391–2400.
20.
RzechorzekNM, ConnickP, LiveseyMR, BorooahS, PataniR, BurrK, StoryD, WyllieDJA, HardinghamGE, ChandranS (2016) Hypothermic preconditioning reverses tau ontogenesis in human cortical neurons and is mimicked by protein phosphatase 2A inhibition. EBioMedicine3, 141–154.
21.
SpolcovaA, MikulaskovaB, HolubovaM, NagelovaV, PirnikZ, ZemenovaJ, HaluzikM, ZeleznaB, GalasMC, MaletinskaL (2015) Anorexigenic lipopeptides ameliorate central insulin signaling and attenuate tau phosphorylation in hippocampi of mice with monosodium glutamate-induced obesity. J Alzheimers Dis45, 823–835.
22.
Long-SmithCM, ManningS, McCleanPL, CoakleyMF, O’HalloranDJ, HolscherC, O’NeillC (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer’s disease. Neuromolecular Med15, 102–114.
23.
PorterDW, KerrBD, FlattPR, HolscherC, GaultVA (2010) Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab12, 891–899.
24.
LiL, ZhangZF, HolscherC, GaoC, JiangYH, LiuYZ (2012) (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol674, 280–286.
McCleanPL, ParthsarathyV, FaivreE, HolscherC (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci31, 6587–6594.
27.
KimSH, AbbasiF, LamendolaC, LiuA, ArielD, SchaafP, GroveK, TomassoV, OchoaH, LiuYV, ChenYD, ReavenG (2013) Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care36, 3276–3282.
28.
DoddGT, LuckmanSM (2013) Physiological roles of GPR10 and PrRP signaling. Front Endocrinol (Lausanne)4, 20.
29.
MikulaskovaB, HolubovaM, PrazienkovaV, ZemenovaJ, HrubaL, HaluzikM, ZeleznaB, KunesJ, MaletinskaL (2018) Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study. Nutr Diabetes8, 5.
30.
EllacottKL, LawrenceCB, RothwellNJ, LuckmanSM (2002) PRL-releasing peptide interacts with leptin to reduce food intake and body weight. Endocrinology143, 368–374.
31.
GrecoSJ, SarkarS, CasadesusG, ZhuX, SmithMA, AshfordJW, JohnstonJM, TezapsidisN (2009) Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett455, 191–194.
32.
GrecoSJ, BryanKJ, SarkarS, ZhuX, SmithMA, AshfordJW, JohnstonJM, TezapsidisN, CasadesusG (2010) Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis19, 1155–1167.
33.
GrecoSJ, SarkarS, JohnstonJM, TezapsidisN (2009) Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun380, 98–104.
34.
SchindowskiK, BrettevilleA, LeroyK, BegardS, BrionJP, HamdaneM, BueeL (2006) Alzheimer’s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol169, 599–616.
35.
PopelovaA, PrazienkovaV, NeprasovaB, KasperovaBJ, HrubaL, HolubovaM, ZemenovaJ, BlumD, ZeleznaB, GalasMC, KunesJ, MaletinskaL (2018) Novel lipidized analog of prolactin-releasing peptide improves memory impairment and attenuates hyperphosphorylation of tau protein in a mouse model of tauopathy. J Alzheimers Dis62, 1725–1736.
36.
PrazienkovaV, HolubovaM, PelantovaH, BuganovaM, PirnikZ, MikulaskovaB, PopelovaA, BlechovaM, HaluzikM, ZeleznaB, KuzmaM, KunesJ, MaletinskaL (2017) Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity. PLoS One12, e0183449.
37.
TardivelM, BegardS, BoussetL, DujardinS, CoensA, MelkiR, BueeL, ColinM (2016) Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Commun4, 117.
38.
BlechováM, NagelováV, ZákováL, DemianováZ, ZeleznáB, MaletínskáL (2013) New analogs of the CART peptide with anorexigenic potency: The importance of individual disulfide bridges. Peptides39, 138–144.
39.
LeeG, LeugersCJ (2012) Tau and tauopathies. Prog Mol Biol Transl Sci107, 263–293.
40.
Buee-ScherrerV, CondaminesO, Mourton-GillesC, JakesR, GoedertM, PauB, DelacourteA (1996) AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer’s disease. Brain Res Mol Brain Res39, 79–88.
41.
AvilaJ, Diaz-NidoJ (2004) Tangling with hypothermia. Nat Med10, 460–461.
42.
Zheng-FischhoferQ, BiernatJ, MandelkowEM, IllenbergerS, GodemannR, MandelkowE (1998) Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem252, 542–552.
43.
AugustinackJC, SchneiderA, MandelkowEM, HymanBT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol103, 26–35.
44.
MaletinskaL, NagelovaV, TichaA, ZemenovaJ, PirnikZ, HolubovaM, SpolcovaA, MikulaskovaB, BlechovaM, SykoraD, LacinovaZ, HaluzikM, ZeleznaB, KunesJ (2015) Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration. Int J Obes (Lond)39, 986–993.
45.
YangY, ZhangJ, MaD, ZhangM, HuS, ShaoS, GongCX (2013) Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis37, 637–648.
46.
GordonJ, AminiS, WhiteMK (2013) General overview of neuronal cell culture. Methods Mol Biol1078, 1–8.
47.
IshiguroK, ShiratsuchiA, SatoS, OmoriA, AriokaM, KobayashiS, UchidaT, ImahoriK (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett325, 167–172.
48.
HangerDP, SeereeramA, NobleW (2009) Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease. Expert Rev Neurother9, 1647–1666.
49.
PlanelE, SunX, TakashimaA (2002) Role of GSK-3β in Alzheimer’s disease pathology. Drug Dev Res56, 491–510.
50.
MaletinskaL, SpolcovaA, MaixnerovaJ, BlechovaM, ZeleznaB (2011) Biological properties of prolactin-releasing peptide analogs with a modified aromatic ring of a C-terminal phenylalanine amide. Peptides32, 1887–1892.
51.
KanoskiSE, HayesMR, SkibickaKP (2016) GLP-1 and weight loss: Unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol310, R885–895.
52.
TianQ, WangJ (2002) Role of serine/threonine protein phosphatase in Alzheimer’s disease. Neurosignals11, 262–269.
